Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

261
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
261
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

247
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
247
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

264
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
264
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

206
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

The journal of allergy and clinical immunology. In practice·2026
Same author

No evidence of a differential treatment effect with omalizumab versus placebo across baseline IgE level and BMI subgroups in patients with chronic spontaneous urticaria.

The journal of allergy and clinical immunology. In practice·2026
Same author

Values-Based Healthcare and the Quintuple Aim: Connection, Compassion, Equity, & Stewardship.

The journal of allergy and clinical immunology. In practice·2026
Same author

The pro-doc-tivity pause: Health economic benefits of collegial connection.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and the Clinical Immunology Society (CIS).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Related Experiment Video

Updated: Jul 2, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K

Digital inhalers for asthma management.

Giselle Mosnaim1,2, Melinda Rathkopf3,4

  • 1Division of Allergy & Immunology, Department of Medicine, Endeavor Health, Glenview.

Current Opinion in Pulmonary Medicine
|February 27, 2024
PubMed
Summary
This summary is machine-generated.

Digital inhaler systems improve asthma control by increasing adherence to controller medications. Overcoming implementation barriers is key to wider adoption for better patient outcomes.

More Related Videos

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

853
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.7K

Related Experiment Videos

Last Updated: Jul 2, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

853
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.7K

Area of Science:

  • Pulmonary Medicine
  • Digital Health
  • Asthma Management

Background:

  • Digital inhaler systems have been available for over 10 years but have limited clinical use.
  • Asthma management remains a significant public health challenge.
  • Barriers to implementation hinder the widespread adoption of digital inhaler technology.

Approach:

  • This review synthesizes current evidence on digital inhaler systems.
  • It identifies barriers to clinical implementation.
  • Potential solutions and facilitators for adoption are discussed.

Key Points:

  • Digital inhalers improve controller medication adherence and reduce quick-relief medication use.
  • Clinical trials show improved asthma control with digital inhaler use.
  • Telemedicine advancements, particularly during the COVID-19 pandemic, have accelerated digital health adoption.

Conclusions:

  • Digital inhaler systems offer significant benefits for asthma management.
  • Addressing implementation challenges in patient education, clinical workflow, and administrative processes is crucial.
  • Increased adoption of digital inhalers can lead to improved asthma outcomes and patient care.